A phase 3b, open-label, multi-center study on durvalumab in combination with gemcitabine-based chemotherapy as 1L treatment for the Chinese patients with unresectable Biliary Tract Cancers (BTC)

Trial Identifier: D933AL00006
Sponsor: AstraZeneca
Start Date: July 2023
Primary Completion Date: February 2025
Study Completion Date: February 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100210
CN Beijing, CN, 100142
CN Changsha, CN, 410013
CN Chongqing, CN, 400038
CN fuzhou, CN, 350011
CN Guangzhou, CN, 510280
CN Harbin, CN, 150049
CN Hefei, CN, 230001
CN Hefei, CN, 230022
CN Jinan, CN, 250117
CN Nanchang, CN, 330000
CN Shanghai, CN, 200032
CN Shenyang, CN, 110001
CN Tianjin, CN, 300050
CN Tianjin, CN, 300060
CN Wuhan, CN, 430071
CN Wuhan, CN, 430030
CN Xi’an, CN, 710061
CN Xiamen, CN, 361015